Search

Your search keyword '"ALINGS, MARCO"' showing total 555 results

Search Constraints

Start Over You searched for: Author "ALINGS, MARCO" Remove constraint Author: "ALINGS, MARCO"
555 results on '"ALINGS, MARCO"'

Search Results

1. Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation

3. Attrition and Adherence in a Web-Based Distress Management Program for Implantable Cardioverter Defibrillator Patients (WEBCARE): Randomized Controlled Trial

5. Apixaban vs Aspirin According to CHA2DS2-VASc Score in Subclinical Atrial Fibrillation: Insights From ARTESiA

8. Multicenter, Phase 2, Randomized Controlled Study of the Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of Rapid Ventricular Rate in Patients With Symptomatic Atrial Fibrillation (ReVeRA-201)

9. Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial

10. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

11. Economic evaluation of remote monitoring of patients with an implantable cardiac defibrillator (REMOTE-CIED study).

12. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

13. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

15. Treatment and Management of Upper Extremity Dysfunction Following Transradial Percutaneous Coronary Intervention:A Prospective Cohort Study

16. Mitral Annular Disjunction in Idiopathic Ventricular Fibrillation Patients: Just a Bystander or a Potential Cause?

17. Cardioversion strategy impacts rate control during recurrences in patients with paroxysmal atrial fibrillation:A subanalysis of the RACE 7 ACWAS trial

18. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

19. Efficacy and Safety of Appropriate Shocks and Antitachycardia Pacing in Transvenous and Subcutaneous Implantable Defibrillators: An Analysis of All Appropriate Therapy in the PRAETORIAN trial

20. The Genetic Basis of Apparently Idiopathic Ventricular Fibrillation – a Retrospective Overview

21. Direct Oral Anticoagulants for Stroke Prevention in Patients with Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials

22. Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation

23. A Multicenter, Phase 2, Randomized, Controlled Study of the Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of Rapid Ventricular Rate in Patients with Symptomatic Atrial Fibrillation (ReVeRA-201)

24. Prognostic Value of Histopathological Thrombus Age in Large Vessel Occlusion-Related Stroke

25. Risk Factors for Infections Involving Cardiac Implanted Electronic Devices

27. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin

28. Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial

29. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

30. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial

31. Prevention of Arrhythmia Device Infection Trial: The PADIT Trial

32. Cardioversion strategy impacts rate control during recurrences in patients with paroxysmal atrial fibrillation: A subanalysis of the RACE 7 ACWAS trial

33. A global survey of health care workers' awareness of non‐alcoholic fatty liver disease: The AwareNASH survey

34. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial

35. Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial

36. Association of the Timing and Extent of Cardiac Implantable Electronic Device Infections With Mortality

37. Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial

40. Cardioversion strategy impacts rate control during recurrences in patients with paroxysmal atrial fibrillation: A subanalysis of the RACE 7 ACWAS trial.

41. Treatment and Management of Upper Extremity Dysfunction Following Transradial Percutaneous Coronary Intervention: A Prospective Cohort Study.

42. Importance of Systematic Diagnostic Testing in Idiopathic Ventricular Fibrillation

43. The genetic basis of apparently idiopathic ventricular fibrillation:A retrospective overview

44. A global survey of health care workers' awareness of non-alcoholic fatty liver disease:The AwareNASH survey

45. Self-Administered Intranasal Etripamil Using a Symptom-Prompted, Repeat-Dose Regimen for Atrioventricular-Nodal-Dependent Supraventricular Tachycardia (RAPID): A Multicentre, Randomised Trial

46. Prognostic Value of Histopathological Thrombus Age in Large Vessel Occlusion-Related Stroke

47. The Genetic Basis of Apparently Idiopathic Ventricular Fibrillation - a Retrospective Overview

48. A global survey of health care workers' awareness of non-alcoholic fatty liver disease: The AwareNASH survey

49. The Importance of Systematic Diagnostic Testing in Idiopathic Ventricular Fibrillation: Results From the Dutch iVF-Registry

50. Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis

Catalog

Books, media, physical & digital resources